Effectiveness of Ketamine for Depression and Suicidal Ideation in the Emergency Department
Brief Summary
The purpose of this study is to examine the effect of a low-dose ketamine infusion on depression symptoms within the Emergency Department (ED) visit, and healthcare utilization after leaving the ED, when administered in the ED for depression or suicidal ideation.
Condition or Disease
- Depression
- Depression Severe
- Depression Acute
- Depression and Suicide
- Suicidal Ideation
Phase
Study Design
Study type: | Interventional |
---|---|
Status: | Completed |
Study results: | No Results Available |
Age: | 18 Years and older (Adult, Older Adult) |
Enrollment: | 29 () |
Funded by: | Other |
Masking |
Clinical Trial Dates
Start date: | Oct 18, 2019 | |
---|---|---|
Primary Completion: | May 31, 2020 | |
Completion Date: | May 31, 2020 | |
Study First Posted: | Feb 12, 2020 | |
Results First Posted: | Aug 31, 2020 | |
Last Updated: | Sep 01, 2020 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Location
Patients will be identified based on either a chief complaint of suicidal ideation, suicide attempt, or severe depression, or if the patient indicates during intake assessment that they have thoughts of harming or killing their self. Identified patients will be assessed by the ED provider for inclusion and exclusion criteria. If the patient is a candidate for the trial and gives their informed consent for enrollment, they will be randomized to receive either ketamine or placebo by a computer program that maintains blinding. The patient will be assessed by psychiatry for disposition and treatment plan prior to receiving the study drug, and will be reassessed four hours after the infusion. Thirty days after the patient leaves the hospital (either leaves from the ED or is discharged from inpatient admission), they will be contacted to follow up on their healthcare utilization after discharge.
Eligibility Criteria
Sex: | All |
---|---|
Minimum Age: | 18 |
More Details
NCT Number: | NCT04266288 |
---|---|
Other IDs: | MMC2019-46 |
Study URL: | https://ClinicalTrials.gov/show/NCT04266288 |
Last updated: Jun 17, 2022